Loading…
Loading…
EQUITY / NASDAQ · XNCM
Mangoceuticals, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.4371 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.4371 USD · Volume 877,230
681 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 68,757 USD | 168,109 USD | -59.10% |
| Operating profit | -1,033,040 USD | -5,268,495 USD | — |
| Net income | -1,312,653 USD | -5,415,818 USD | — |
| Cash and cash equivalents | 228,688 USD | — | — |
| Total liabilities | 1,648,969 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 228,688 USD | — | — | 1,486,338 USD | 1,486,338 USD | 481,281 USD | — | — |
| Gross profitIncome statement | 44,215 USD | 73,216 USD | — | — | 250,386 USD | 50,899 USD | 202,911 USD | 89,948 USD |
| Net incomeIncome statement | -1,312,653 USD | -4,715,803 USD | -3,403,141 USD | — | -20,642,994 USD | -7,618,218 USD | -17,873,427 USD | -5,415,818 USD |
| Operating profitIncome statement | -1,033,040 USD | -4,159,366 USD | — | — | -18,032,349 USD | -7,542,926 USD | -17,664,610 USD | -5,268,495 USD |
| RevenueIncome statement | 68,757 USD | 136,621 USD | — | — | 456,021 USD | 84,246 USD | 361,661 USD | 168,109 USD |
| Total assetsBalance sheet | 14,172,795 USD | — | — | 16,089,573 USD | 16,089,573 USD | 16,531,802 USD | — | — |
| Total equityBalance sheet | 12,525,944 USD | — | 13,474,652 USD | 15,200,547 USD | 15,200,547 USD | 15,729,266 USD | — | 19,241,883 USD |
| Total liabilitiesBalance sheet | 1,648,969 USD | — | — | 890,568 USD | 890,568 USD | 804,275 USD | — | — |
| Financing cash flowCash flow statement | — | 316,944 USD | — | — | 7,270,855 USD | — | 5,187,356 USD | — |
| Operating cash flowCash flow statement | — | -1,571,849 USD | — | — | -5,850,255 USD | — | -4,772,494 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 04/01/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.